205 related articles for article (PubMed ID: 31637961)
21. IARC use of oxidative stress as key mode of action characteristic for facilitating cancer classification: Glyphosate case example illustrating a lack of robustness in interpretative implementation.
Bus JS
Regul Toxicol Pharmacol; 2017 Jun; 86():157-166. PubMed ID: 28274811
[TBL] [Abstract][Full Text] [Related]
22. The comet assay with multiple mouse organs: comparison of comet assay results and carcinogenicity with 208 chemicals selected from the IARC monographs and U.S. NTP Carcinogenicity Database.
Sasaki YF; Sekihashi K; Izumiyama F; Nishidate E; Saga A; Ishida K; Tsuda S
Crit Rev Toxicol; 2000 Nov; 30(6):629-799. PubMed ID: 11145306
[TBL] [Abstract][Full Text] [Related]
23. The contribution of molecular epidemiology to the identification of human carcinogens: current status and future perspectives.
Boffetta P; Islami F
Ann Oncol; 2013 Apr; 24(4):901-8. PubMed ID: 23136234
[TBL] [Abstract][Full Text] [Related]
24. A review on arsenic carcinogenesis: Epidemiology, metabolism, genotoxicity and epigenetic changes.
Zhou Q; Xi S
Regul Toxicol Pharmacol; 2018 Nov; 99():78-88. PubMed ID: 30223072
[TBL] [Abstract][Full Text] [Related]
25. Categorizing the characteristics of human carcinogens: a need for specificity.
Smith CJ; Perfetti TA; Hayes AW; Berry SC; Trosko JE; King JA; Goodman JI; Begley CG; Dayan A
Arch Toxicol; 2021 Aug; 95(8):2883-2889. PubMed ID: 34148101
[TBL] [Abstract][Full Text] [Related]
26. Short-term tests for defining mutagenic carcinogens.
Waters MD; Stack HF; Jackson MA
IARC Sci Publ; 1999; (146):499-536. PubMed ID: 10353401
[TBL] [Abstract][Full Text] [Related]
27. Use of mechanistic data in IARC evaluations.
Cogliano VJ; Baan RA; Straif K; Grosse Y; Secretan B; El Ghissassi F
Environ Mol Mutagen; 2008 Mar; 49(2):100-9. PubMed ID: 18240161
[TBL] [Abstract][Full Text] [Related]
28. IARC monographs, industry influence, and upgrading, downgrading, and under-grading chemicals: a personal point of view. International Agency for Research on Cancer.
Huff J
Int J Occup Environ Health; 2002; 8(3):249-70. PubMed ID: 12358081
[TBL] [Abstract][Full Text] [Related]
29. Carcinogenicity evaluations and ongoing studies: the IARC databases.
Vainio H; Coleman M; Wilbourn J
Environ Health Perspect; 1991 Dec; 96():5-9. PubMed ID: 1820277
[TBL] [Abstract][Full Text] [Related]
30. Chemicals and industrial processes associated with cancer in humans. IARC Monographs, Volumes 1 to 20.
Althouse R; Huff J; Tomatis L; Wilbourn J
IARC Monogr Eval Carcinog Risk Chem Hum Suppl; 1979 Sep; (1):1-71. PubMed ID: 296141
[TBL] [Abstract][Full Text] [Related]
31. A novel, integrated in vitro carcinogenicity test to identify genotoxic and non-genotoxic carcinogens using human lymphoblastoid cells.
Wilde EC; Chapman KE; Stannard LM; Seager AL; Brüsehafer K; Shah UK; Tonkin JA; Brown MR; Verma JR; Doherty AT; Johnson GE; Doak SH; Jenkins GJS
Arch Toxicol; 2018 Feb; 92(2):935-951. PubMed ID: 29110037
[TBL] [Abstract][Full Text] [Related]
32. [Genotoxicity of carcinogenic substances in humans and animals].
Malaveille C; Bartsch H
J Toxicol Clin Exp; 1989; 9(2 Pt 2):15-25. PubMed ID: 2677321
[TBL] [Abstract][Full Text] [Related]
33. Man-made mineral (vitreous) fibres: evaluations of cancer hazards by the IARC Monographs Programme.
Baan RA; Grosse Y
Mutat Res; 2004 Sep; 553(1-2):43-58. PubMed ID: 15288532
[TBL] [Abstract][Full Text] [Related]
34. 1,3-Butadiene, isoprene and chloroprene: reviews by the IARC monographs programme, outstanding issues, and research priorities in epidemiology.
Rice JM; Boffetta P
Chem Biol Interact; 2001 Jun; 135-136():11-26. PubMed ID: 11397378
[TBL] [Abstract][Full Text] [Related]
35. From hazard identification to weighing the benefits and drawbacks of prevention.
Vainio H; Weiderpass E
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):28-33. PubMed ID: 16005922
[TBL] [Abstract][Full Text] [Related]
36. Cobalt and antimony: genotoxicity and carcinogenicity.
De Boeck M; Kirsch-Volders M; Lison D
Mutat Res; 2003 Dec; 533(1-2):135-52. PubMed ID: 14643417
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of non-genotoxic carcinogens and importance of a weight of evidence approach.
Hernández LG; van Steeg H; Luijten M; van Benthem J
Mutat Res; 2009; 682(2-3):94-109. PubMed ID: 19631282
[TBL] [Abstract][Full Text] [Related]
38. On the International Agency for Research on Cancer classification of glyphosate as a probable human carcinogen.
Tarone RE
Eur J Cancer Prev; 2018 Jan; 27(1):82-87. PubMed ID: 27552246
[TBL] [Abstract][Full Text] [Related]
39. Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties.
McGregor D
Crit Rev Toxicol; 2007; 37(10):887-914. PubMed ID: 18027166
[TBL] [Abstract][Full Text] [Related]
40. How well can carcinogenicity be predicted by high throughput "characteristics of carcinogens" mechanistic data?
Becker RA; Dreier DA; Manibusan MK; Cox LAT; Simon TW; Bus JS
Regul Toxicol Pharmacol; 2017 Nov; 90():185-196. PubMed ID: 28866267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
